The Phase 2 clinical trial of MetiMedi Pharmaceutical Co., Ltd.’s anticancer drug OMT-111 (Pre-filled Syringe Formulation) is progressing smoothly as planned, with the last patient currently under administration.

Once the final patient dosing is completed, the Phase 2 trial will be concluded and the results will be analyzed and reported to the Ministry of Food and Drug Safety of Korea.

In addition, MetiMedi plans to prepare a journal publication of the trial results and present them at international conferences, while also initiating global marketing activities targeting multinational pharmaceutical companies.

Furthermore, OMT-111 has been developed into an oral enteric-coated capsule formulation, Meti-101, to improve patient convenience and broaden its potential applications.

On April 21, 2022, the Phase 1b/2a clinical trial of Meti-101 was approved by the Ministry of Food and Drug Safety of the Republic of Korea, and on August 11, 2022, it received conditional IRB approval from Gachon University Gil Medical Center. Final approval is expected following submission of additional requested documents.

Upon IRB approval, the clinical trial contract will be signed and the study will commence with a planned enrollment of 30 patients.